In the last few years there have been substantial advances in the field of hemophilia treatment, that were undoubtedly a reaction of the scientific community to the nightmare of the HIV epidemics. Clotting factor concentrates are becoming safer and safer in terms of risk of transmission of bloodborne viral infections. The risk of transmission of HIV is to be considered negligible, barring human error. There is still a rare risk of hepatitis transmission, which should be tackled through the improvement of virus removal methods. Plasma-derived concentrates are also becoming purer and purer. There is some evidence that very high purity plasma products obtained using monoclonal antibody technology slow the loss of CD4-lymphocytes in HIV positive hemophiliacs. Factor VIII made from recombinant DNA technology is licensed in several countries. It is efficacious and hopefully free from the risk of transmitting viruses. It is still debated whether this product enhances the development of inhibitor antibodies. Finally, current explosive progress in molecular biology allows to foresee the achievement within the decade of successful gene replacement therapy for hemophilia.
|Translated title of the contribution||Modern treatment of hemophilia: From the shadows towards the light|
|Number of pages||9|
|Publication status||Published - 1994|
- clotting factor concentrates
- recombinant factor VIII
- virus inactivation
ASJC Scopus subject areas